Mechano growth factor (MGF)

What Mechano growth factor (MGF) does

MGF usually means a synthetic fragment linked to an IGF-1 splice variant. People inject it for muscle growth and injury recovery. Some animal and cell studies found effects, but an independent muscle-cell study did not reproduce them. No human dosing study or reliable safety rate was found.

• In animal studies, MGF and a related peptide improved tendon healing and ligament strength. (animal)
• Early lab work found more muscle-cell growth, but a later independent cell study did not repeat it. (animal)
• People report using it for muscle growth and injury recovery; no human study has tested this. (Reported by users)

Uses in the sources

• People report use for muscle growth; no controlled human benefit has been demonstrated. (Reported by users) (source)
• People discuss injury or workout recovery; animal MGF findings cannot establish human benefit. (Reported by users) (source)

Mechano growth factor (MGF) dosage

Typical reported dose: 100–200 mcg after workouts

• 100–200 mcg after training: 100–200 mcg, described as bilateral dosing after workouts; days per week not stated, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• 100 mcg on four training days: 100 mcg MGF on each listed day monday, Tuesday, Thursday and Friday, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• 100 mcg before training: 100 mcg per reported administration before workouts; days per week not stated, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• 50 mcg after training, three days: 50 mcg into trained muscles; total across sites is unclear monday, Wednesday and Friday, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Mechano growth factor (MGF)

Comes as: Powder vial for mixing; community reports..

Mixed with: Community posts describe bacteriostatic water. Compatibility and stability are not established..

Common vial sizes: 2 mg. Common water amounts: mL.

• Vial sizes and water volumes are examples in posts, not a measured market distribution.
• No approved mixing instructions or beyond-use date exists for these reported products.
• Bacteriostatic water does not sterilize contaminated powder.
• A forum describes 2 mg vials and bacteriostatic water but gives no clearly verified MGF-specific water volume.

Before mixing: No validated product-specific temperature, shelf life or shipping-stability data were found.

After mixing: No validated storage temperature or usable lifetime after mixing was found. Clear appearance does not prove sterility.

Mechano growth factor (MGF) side effects and risks

Reported side effects

• Injection-site pain, bruising or bleeding: No compound specific human rate. These are injection route risks., moderate. Persistent pain, a growing lump or bleeding needs assessment. (source)
• Infection or tissue injury from an unregulated injection: No MGF specific rate or denominator was found., serious. Spreading redness, fever or severe pain needs urgent assessment. (source)
• Allergic or immune reaction: Possible with an injection or its ingredients; no MGF specific human rate., serious. Breathing trouble, swelling or fainting requires emergency care. (source)
• Blood-sugar changes, theoretical: No direct human evidence for this peptide. Risk is extrapolated from the wider hormone drug setting., serious. Check glucose with symptoms, particularly with insulin or glucose-lowering pills. (source)

Stop and get help if

• Trouble breathing, throat or tongue swelling, fainting or widespread hives after exposure: Stop exposure and call emergency services immediately. Use prescribed emergency allergy treatment if available.
• Confusion, seizure, unconsciousness or low blood sugar that does not resolve: Get emergency care. Do not give food or drink to someone who cannot swallow safely.
• Hot, spreading injection-site redness, fever, pus or rapidly worsening pain: Stop injections and seek urgent medical assessment for infection or tissue injury.
• Chest pain, severe breathlessness, collapse or new neurological symptoms: Call emergency services now. Tell the team about all peptides and other drugs used.
• Severe muscle pain or swelling with numbness after a muscle injection: Seek emergency care for possible bleeding or pressure injury in the muscle.

Who should avoid it

• under18: Precaution: no pediatric dosing or safety study of this synthetic peptide was found.
• pregnant: Precaution: pregnancy and fetal safety have not been studied.
• breastfeeding: Precaution: breast-milk transfer and infant effects are unknown.
• tryingToConceive: Precaution: fertility effects and a safe time to stop before conception are unknown.
• activeCancer: Precaution: MGF E peptide promoted prostate cancer-cell growth in culture. Human cancer risk has not been measured.
• cancerHistory: Review prior cancer with the treating clinician. A laboratory cell-growth signal exists; human recurrence risk is unknown.
• diabetes: Blood-sugar effects are uncharacterized. Insulin and some diabetes pills already raise low-sugar risk.
• heartCondition: Animal heart findings do not establish human safety. New swelling or breathlessness needs assessment.
• kidneyDisease: Clearance in kidney disease is unknown. Kidney problems also change blood-sugar and bleeding risks.
• liverDisease: No dosing adjustment is established. Liver disease can complicate interpretation of IGF-1 tests and bleeding risk.
• bleedingDisorder: Muscle injections can cause bleeding or a deep collection of blood. This is a route risk, not a proven peptide effect.
• testedAthlete: WADA 2026 prohibits mechano growth factors at all times under S2.3. PEG modification does not make an analogue permitted.
• other: Avoid a substance that previously caused a serious allergic reaction. Actual vial ingredients may be uncertain.

Interactions

• Insulin: Insulin causes low blood sugar. Any added effect of this peptide is untested; symptoms need a glucose check.
• Sulfonylureas and meglitinides: These pills can cause low blood sugar. No interaction study with MGF or PEG-MGF establishes a safe combination.
• Growth hormone, IGF-1 and GH-releasing drugs: Stacking adds untested growth and metabolic exposures. Human safety and claims about optimal spacing are unproven.
• Anticoagulants and antiplatelet drugs: Muscle punctures can bleed or bruise more on these drugs. A direct chemical interaction with the peptide is unknown.
• PEG-MGF: Related products may be duplicated in a stack. No human study establishes combined exposure or benefit.

Product quality risks

• Two illicit MGF preparations contained a C-terminal amidated analogue. This small identity study cannot estimate market-wide quality.
• A separate illicit full-length MGF product contained a modified 12,264.9 Da protein. The MGF name can cover different molecules.
• Unregulated vials may have the wrong identity or amount, impurities, microbes or bacterial toxins. No compound-specific contamination rate is established.

What to expect

No human administration study found. Human-derived cell work and animal findings are mixed; they do not establish dosing.

Key studies

• Early muscle-cell findings: An early experiment reported more muscle-cell growth and delayed maturation with the MGF E-domain. (source)
• Human muscle cells transplanted into mice: MGF peptide improved human-cell engraftment in mice, not in human recipients. (source)
• Human muscle cells in a dish: MGF-E affected younger donor cells in culture; it was never administered to the donors. (source)
• MGF effects failed replication: MGF fragments did not reproduce the muscle-cell effects reported in earlier work. (source)
• Injured Achilles tendon in rats: An MGF-related peptide improved measures of tendon healing in rats. (source)
• MGF analogue after a mouse heart attack: A stabilized MGF analogue improved heart pumping measures, but did not prevent heart enlargement. (source)

Mechano growth factor (MGF) FAQ

• Is Mechano growth factor (MGF) FDA-approved? No approved product, label or indication found. Category 3 is an inadequate-nomination finding, not a demonstrated safety finding.
• How do people take it? Into muscle, after workouts; days per week not stated. Source: reported by users, not an established dose.
• What's the difference between Mechano growth factor (MGF) and IGF-1 LR3? Mechano growth factor (MGF): a muscle-repair peptide idea with mixed lab findings and no human dosing studies. IGF-1 LR3: an unapproved growth signal with no human trials found. Why people pair them: users combine or alternate peptides for hoped-for muscle growth. Timing advice conflicts.
• Can I take it with IGF-1 LR3? Users combine or alternate peptides for hoped-for muscle growth. Timing advice conflicts. No human combination study was found. Added harms and effective exposure are unknown. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). MGFs are named. S2 also covers substances with similar structure or effects, including PEGylated analogues.
• How long does a mixed vial last? No validated storage temperature or usable lifetime after mixing was found. Clear appearance does not prove sterility.